Knowing early whether a woman is high-risk or low-risk for pre-eclampsia can provide different monitoring and prevention, changing the immediate and long term health of both mothers and babies.

A reliable screening test can identify those at higher risk of developing the condition before 36-37 weeks, enabling earlier intervention.

Science strongly suggests that initiating low-dose aspirin before the 16th week can reduce the risk of developing pre-eclampsia in a high-risk population by 50-70%. This preventive measure can significantly improve maternal and child health, minimizing growth restriction, pre-term deliveries, and maternal organ damage.